Publicacións nas que colabora con JOSE RAMON GONZALEZ JUANATEY (56)

2024

  1. Biocompatibility Testing of UV-Curable Polydimethylsiloxane for Human Umbilical Vein Endothelial Cell Culture on-a-Chip

    ACS Omega, Vol. 9, Núm. 28, pp. 30281-30293

  2. Edoxaban treatment in a post-infarction experimental model

    European Journal of Pharmacology, Vol. 962

2023

  1. Cost Analysis of Magnetic Resonance Imaging and Computed Tomography in Cardiology: A Case Study of a University Hospital Complex in the Euro Region

    Healthcare (Switzerland), Vol. 11, Núm. 14

  2. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  3. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  4. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1

  2. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

  3. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value

    Journal of Molecular Medicine, Vol. 99, Núm. 12, pp. 1741-1753

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170

  2. Inflammatory effects of in vivo glycated albumin from cardiovascular patients

    Biomedicine and Pharmacotherapy, Vol. 113

  3. Obesity-Related Genetic Determinants of Heart Failure Prognosis

    Cardiovascular Drugs and Therapy, Vol. 33, Núm. 4, pp. 415-424

  4. The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 29, Núm. 10, pp. 1050-1060

2018

  1. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium

    British Journal of Clinical Pharmacology, Vol. 84, Núm. 2, pp. 280-291

2017

  1. Evolution and bad prognostic value of advanced glycation end products after acute heart failure: Relation with body composition

    Cardiovascular Diabetology, Vol. 16, Núm. 1

  2. Laser technique for the fabrication of blood vessels-like models for preclinical studies of pathologies under flow conditions

    Biofabrication, Vol. 9, Núm. 2

  3. Non classical Monocytes Levels, Increased by Subcutaneous Fat-Secretome, Are Associated with Less Rehospitalization after Heart Failure Admission

    Journal of Cardiovascular Translational Research, Vol. 10, Núm. 1, pp. 16-26

  4. Orosomucoid as prognosis factor associated with inflammation in acute or nutritional status in chronic heart failure

    International Journal of Cardiology, Vol. 228, pp. 488-494

2016

  1. 2D-DIGE-based proteomic analysis of intracoronary versus peripheral arterial blood platelets from acute myocardial infarction patients: Upregulation of platelet activation biomarkers at the culprit site

    Proteomics - Clinical Applications, Vol. 10, Núm. 8, pp. 851-858